CAR

Avis Budget Group, Inc.
$167.05
+9.34 (+5.92%)
Mkt Cap 5.90B
Volume 2,053,284
52W Range 85.96-847.7
Sector Industrials
Beta 1.90
EPS (TTM) -18.93
P/E Ratio -5.08
Revenue (TTM) 11.75B
Rev Growth (5Y) +16.6%
EPS Growth (5Y) N/A
AlphaVal · Fair Value
$141.61
Overvalued · Moderate
18.0% above fair value

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 11.65B 11.79B 12.01B 11.99B 9.31B 5.40B 9.17B 9.12B 8.85B 8.66B 8.50B 8.48B
Net Income (889.00M) (1.82B) 1.63B 2.76B 1.28B (684.00M) 302.00M 165.00M 361.00M 163.00M 313.00M 245.00M
EPS -25.26 -51.23 42.61 58.44 19.80 -9.70 4.02 2.08 4.32 1.78 3.02 2.32
Free Cash Flow (11.98B) (6.54B) (11.63B) 576.00M (2.59B) 3.95B (91.00M) (563.00M) 513.00M 482.00M N/A N/A
FCF / Share -340.28 -184.34 -303.66 12.18 -39.97 56.01 -1.21 -7.10 6.15 5.24 N/A N/A
Operating CF 3.30B 3.52B 3.83B 4.71B 3.49B 691.00M 2.59B 2.61B 2.65B 2.63B N/A N/A
Total Assets 32.19B 29.95B 33.42B 25.93B 22.60B 17.54B 23.93B 19.23B 17.84B 17.79B N/A N/A
Total Debt 31.17B 26.04B 26.45B 20.92B 17.80B 13.66B 17.12B 13.78B 12.82B 12.40B N/A N/A
Cash & Equiv 519.00M 537.00M 559.00M 572.00M 537.00M 693.00M 689.00M 620.00M 618.00M 490.00M N/A N/A
Book Value (3.13B) (2.33B) (349.00M) (703.00M) (220.00M) (155.00M) 656.00M 414.00M 573.00M 221.00M N/A N/A
Return on Equity N/A N/A N/A N/A N/A N/A 0.46 0.40 0.63 0.74 N/A N/A
CAR News
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
May 21, 2026 04:30 AM · globenewswire.com
Qihan Biotech Announces FDA Clearance of IND for QT-019C, a universal dual-target CAR-T candidate, marking a significant milestone in the development of a potentially low-lymphodepletion, off-the-shelf CAR-T therapy for autoimmune diseases
May 20, 2026 05:00 AM · businesswire.com
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
May 19, 2026 12:05 PM · globenewswire.com
Avis Budget's Pricing Recovery Signals Improving Industry Discipline
May 19, 2026 06:25 AM · zacks.com
CAR's Recovery Remains Weak After Extreme Volatility: Hold or Fold?
May 18, 2026 09:20 AM · zacks.com
Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune
May 14, 2026 06:46 AM · seekingalpha.com
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
May 12, 2026 12:05 PM · globenewswire.com
OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
May 12, 2026 04:00 AM · globenewswire.com
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy
May 11, 2026 04:55 AM · prnewswire.com
CAPREIT Reports First Quarter 2026 Results
May 07, 2026 01:00 PM · globenewswire.com